Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8781590 | 0.81 | CA12 (0.41) | MEN1KMT2AALOX15LMNAMMP1 | |
| SCHEMBL4515826 | 0.77 | KMT2A (0.45) | MEN1KMT2AALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL4498446 | 0.77 | KMT2A (0.45) | MEN1KMT2AALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL14880190 | 0.76 | — | — | |
| SCHEMBL2313506 | 0.76 | RAB9A (0.38) | — | |
| SCHEMBL53004 | 0.74 | LMNA (0.36) | ALOX15LMNA | |
| SCHEMBL8173094 | 0.73 | — | — | |
| SCHEMBL5327501 | 0.73 | KMT2A (0.50) | MEN1KMT2AALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL2777834 | 0.73 | MEN1 (0.45) | MEN1KMT2AALOX15HSD17B10SMN1; SMN2 | |
| SCHEMBL9847817 | 0.71 | KMT2A (0.48) | MEN1KMT2AALOX15HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106634051-A | Anti-mold acrylic ester modified calcium carbonate packing and preparation method thereof | 安徽九子山塑业有限公司 | 2017-05-10 | — | — | CN | claimed |
| US-6958359-B1 | Vanadium compounds as anti-angiogenic agents | PARKER HUGHES INSTITUTE (US) | 2005-10-25 | — | — | US | claimed |
| CN-107376189-B | Preparation method and application of heavy metal chelating agent | 武汉强丰新特科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2021067259-A1 | LAMELLAR IRON SULFIDES WITH EMBEDDED CATIONS FOR ELECTRICAL ENERGY STORAGE | THE UNIVERSITY OF CHICAGO (US) | 2021-04-08 | — | — | WO | disclosed |
| CN-106634051-A | Anti-mold acrylic ester modified calcium carbonate packing and preparation method thereof | 安徽九子山塑业有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-102443471-A | Extreme pressure resistant additive for industrial gear oil | TIANJIN GONGBO SCI TECH DEV CO | 2012-05-09 | — | — | CN | disclosed |
| US-20060183729-A1 | Vanadium compounds as anti-angiogenic agents | PARKER HUGHES INSTITUTE (US) | 2006-08-17 | — | — | US | disclosed |
| US-7091351-B2 | Vanadium compounds for treating cancer | PARKER HUGHES INSTITUTE (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060106006-A1 | Vanadium compounds for treating cancer | PARKER HUGHES INSTITUTE (US) | 2006-05-18 | — | — | US | disclosed |
| US-6958359-B1 | Vanadium compounds as anti-angiogenic agents | PARKER HUGHES INSTITUTE (US) | 2005-10-25 | — | — | US | disclosed |
| US-6878388-B1 | Vanadium compounds for treating proliferative cell disorders | PARKER HUGHES INSTITUTE (US) | 2005-04-12 | — | — | US | disclosed |
| US-6432941-B1 | ANTICANCER, ANTITUMOR AGENT | PARKER HUGHES INSTITUTE | 2002-08-13 | — | — | US | disclosed |
| EP-1104432-A1 | VANADIUM COMPOUNDS FOR TREATING CANCER | Parker Hughes Institute (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000035930-A1 | VANADIUM COMPOUNDS FOR TREATING CANCER | PARKER HUGHES INSTITUTE (US) | 2000-06-22 | — | — | WO | disclosed |
| US-5776933-A | Method of inhibiting protease | E. R. SQUIBB & SONS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5760036-A | ENZYME INHIBITORS OF RETROVIRAL PROTEASE FOR PREVENTION OF AIDS | E. R. SQUIBB & SONS, INC. (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0801971-A1 | WASTE GAS AND DUST TREATMENT METHOD | KANEKA CORPORATION (JP) | 1997-10-22 | — | — | EP | disclosed |
| US-5559256-A | Aminediol protease inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5492910-A | AIDS TREATMENT | BRISTOL-MYERS SQUIBB CO. (US) | 1996-02-20 | — | — | US | disclosed |
| EP-0580402-A2 | Aminediol protease inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1994-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183729-A1 | Vanadium compounds as anti-angiogenic agents | KDR, VHL, VEGFA | MEN1 3870/4885KMT2A 2848/4885ALOX15 1475/4885 |
| US-20060106006-A1 | Vanadium compounds for treating cancer | VHL, TP53, VAV1 | MEN1 819/4885KMT2A 741/4885ALOX15 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.